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Abstract 24 
To investigate if there is evidence for a ‘legacy effect’ for BP lowering treatment, that 25 
is worse health outcomes from not initiating drug treatment at a systolic BP threshold 26 
of 140 mmHg in middle-age adults. We systematically reviewed studies comparing 27 
the effects of delayed  BP treatment (placebo/untreated during the trial or no 28 
previous treatment at trial entry) versus early treatment (actively treated during the 29 
trial or previous BP treatment at trial entry) on mortality in the short-term (5-year in-30 
trial period) and long-term (≥10 years in total period). The data were pooled using 31 
Peto ORs. A subgroup analysis by 10-year Framingham risk score was performed. 32 
Three studies (ALLHAT, Oslo and PREVEND-IT) involving 4746 participants were 33 
included. The results were heavily influenced by the ALLHAT trial. We found no 34 
significant difference in all-cause mortality between ‘delayed BP’ and ‘early 35 
treatment’ in the short-term OR 0.95 (95% CI 0.68- 1.32) or long-term OR 0.90 36 
(95%CI 0.78-1.04), with similar results for mortality from cardiovascular disease 37 
(CVD). The effects of delayed BP lowering treatment on long-term all-cause and 38 
CVD mortality did not vary with baseline risk of CVD. The review showed no clinically 39 
adverse ‘legacy effect’ on mortality or major CVD event from not treating middle-40 
aged adults at a systolic BP threshold of 140 mmHg or over. The results were 41 
consistent for all CVD risk subgroups. Although these studies are non-randomised 42 
post-hoc analyses, they may allay concerns that early treatment of elevated systolic 43 
BP is necessary to prevent CVD events in primary prevention populations.  44 
Key words: legacy effect, blood pressure, long-term, all-cause mortality, CVD 45 
mortality, primary prevention, cardiovascular disease 46 
  47 
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Introduction 48 
The effectiveness of blood pressure (BP) lowering drugs to prevent 49 
cardiovascular disease (CVD) has been well established in trials of patients with 50 
diabetes, the elderly, or those with a systolic BP of ≥160 mmHg or over (for example 51 
SHEP1, Syst-Eur2 and HYVET3). However, the effects of BP lowering 52 
pharmacotherapy in middle-aged adults with mildly elevated BP (defined as systolic 53 
BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) are uncertain. A recent 54 
systematic review of participants with mildly elevated BP found no statistically 55 
significant effect of treatment in this patient group on the incidence of CVD events or 56 
mortality (Diao et al 4 ). However, a similar review by the Blood Pressure Lowering 57 
Treatment Trialist’s Collaboration (BPLTTC)5 observed significant reductions in stroke, 58 
CVD and all-cause mortality. Although the BPLTTC review included more trials with a 59 
larger number of participants, these trials evaluated both less versus more intensive 60 
treatments and the addition of new BP treatment to pre-existing medication and so the 61 
comparison was not restricted to active treatment versus placebo/no treatment as in 62 
the Diao et al review. In line with the findings in the Diao et al review4, most of the 63 
placebo trials6-12 in which previous treatments were not permitted or were withdrawn, 64 
did not show substantial effects of active drug treatment on major CVD events, 65 
coronary heart disease (CHD), stroke or all-cause mortality within the trial period.  66 
Concerns have been raised, however, that the effects of delayed treatment may 67 
take longer five years to become evident, and that delaying treatment after a patient 68 
reaches a SBP threshold of 140 mmHg could result in irreversible pathological 69 
damage. Two systematic reviews13, 14 have been conducted of BP lowering trials with 70 
a post-trial follow-up of up to ten years and showed a significantly reduced risk of CVD 71 
and all-cause mortality in the participants randomly allocated to active treatment. 72 
However, these two reviews included patients with pre-existing CVD. Therefore, the 73 
‘legacy effect’ of delayed drug treatment in individuals with mildly elevated SBP without 74 
cardiovascular disease remains uncertain. As there are no trials that addressed this 75 
specific question, the aim of this review is to investigate if there are any adverse 76 
‘legacy effects from not initiating drug treatment at a systolic BP threshold of 140 77 
mmHg in healthy middle-age adults using post-hoc analyses of existing trials with long-78 
term follow up. 79 
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Methods 80 
Protocol and registration 81 
The review protocol was published in the Journal of Medical Internet Research15 and 82 
can be accessed via https://www.researchprotocols.org/2017/9/e177/. The review 83 
was registered in PROSPERO International Prospective Register of Systematic 84 
Reviews: CRD42017058414 85 
Criteria for considering studies for this review 86 
The current review included randomised controlled trials (RCTs) with at least 1-year 87 
post-trial follow-up. Trials including men and non-pregnant women from 30 to 65 years 88 
of age, where at least 80% of participants had mildly elevated BP (defined as a systolic 89 
BP of 140 – 159 mmHg) and no history of CVD (myocardial infarction, angina pectoris, 90 
coronary bypass surgery, coronary angioplasty, stroke, transient ischaemic attack, 91 
carotid endarterectomy, surgery for peripheral vascular disease, intermittent 92 
claudication or renal failure (creatinine > 1.5 times the upper limit of normal)) at 93 
baseline were eligible. We included studies that used a placebo or untreated control 94 
comparator or another active BP lowering treatment where it was possible to 95 
determine participants who had previously been taking blood pressure lowering 96 
treatment (previous treatment) or no pre-existing treatment (treatment naïve). Where 97 
trials included participants different to those of interest (e.g. in secondary prevention 98 
populations, in participants with moderately or highly elevated BP or older than 65 99 
years), we attempted to access data from trial investigators  and subsequently 100 
included only participants meeting our criteria in the analyses. The primary outcome 101 
of the review was all-cause mortality, with secondary outcome of CVD mortality and 102 
CVD events (defined as fatal and non-fatal stroke, fatal and non-fatal CHD, fatal and 103 
non-fatal heart failure).  104 
Data sources and searches 105 
We searched Medline via Ovid (1946 to Sept 2018), Embase via Ovid (1974 to Sept 106 
2018) and the Cochrane Register of Controlled Trials (CENTRAL) (Sept 2018). We 107 
combined text word and MeSH/Emtree terms related to BP lowering drug agents with 108 
hypertension terms and follow-up studies. We used the  Cochrane Highly Sensitive 109 
Search Strategy for identifying randomised trials (sensitivity and precision maximising 110 
2008 revision) in Medline16. No language restrictions were applied. The search 111 
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strategies are provided in Table appendix 1.  We modified the search strategy from 112 
the published protocol15 as the planned method of identifying trials and then searching 113 
for follow-up studies was considered inadequate to identify potentially eligible RCTs.  114 
We searched reference lists of known systematic reviews on post-trial studies of BP 115 
lowering drug treatment (Kostis 201013 and Hirakawa 201714) and meta-analyses of 116 
trials in middle-aged adults with mildly elevated BP4, 5, 17, 18. We contacted 117 
corresponding authors of relevant papers regarding any further published or 118 
unpublished work.  119 
Study selection 120 
Two reviewers (CH and SS) independently scanned the results of the title and abstract 121 
search and any potentially relevant articles were obtained in full text. Two reviewers 122 
then screened the full text of  potentially relevant articles against the reviews inclusion 123 
criteria. Discrepancies were resolved through discussion with a third reviewer.  124 
Data extraction 125 
Data extraction were independently performed by two reviewers (CH and SS). If any 126 
disagreement arose, a third reviewer (JD) was consulted. The extraction form included 127 
details of study characteristics, participant characteristics, interventions and settings, 128 
outcome data, type of analysis used in the studies and follow-up years. 129 
Assessment of risk of bias in included studies 130 
Two review authors (CH and SS) independently assessed risk of bias using the 131 
Cochrane Risk of bias in non-randomised and /randomised studies of interventions 132 
tools 19, 20. The included ALLHAT study was assessed using the tool for non-133 
randomised studies as data from the original randomised trial was reanalysed to 134 
compare non-randomised groups (treatment naïve vs previous treatment) based on 135 
data collected at trial baseline. Risk of bias assessment in both non-randomised 21 and 136 
randomised studies22 included consideration of four mutual domains: bias due to 137 
deviations from intended interventions, bias due to missing data, bias in measurement 138 
of outcomes and bias in selection of the reported. Risk of bias assessment in non-139 
randomised controlled studies required consideration of three further criteria: bias due 140 
to confounding, bias in selection of participants into the study and bias in classification 141 
of intervention. For randomised studies, risk of bias assessment also included 142 
consideration of bias arising from the randomisation process. For the non-randomised 143 
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studies, each risk of bias domain was assessed as low, moderate, serious or critical 144 
risk of bias with a no information response when insufficient data were reported to 145 
permit a judgment. For the randomised studies, each risk of bias domain was 146 
assessed as low, some concerns and high risk of bias. The domain level judgments 147 
provide the basis for an overall risk of bias judgment for each study. An assessment 148 
of potential publication bias was not performed due to the small number of included 149 
studies.  150 
Data analysis 151 
We compared outcomes in the short-term (average 5-year in-trial period) and long-152 
term (an overall period of at least 10 years cumulative in- and post-trial period) 153 
between ‘delayed treatment’ and ‘early treatment’ groups. The ‘early treatment’ group 154 
included who had been previously treated with blood pressure lowering treatment at 155 
trial entry and the ‘delayed treatment’ group included participants who were treatment 156 
naïve using individual patient data from the trial. This approach has been used 157 
previously by Nelson et al23.  158 
Due to the small number of included studies, fixed effect Peto odds ratio (OR) was 159 
used to estimate the pooled effects 24. As recommended25-28, we also used other 160 
methods to test the robustness of the results in sensitivity analyses. Heterogeneity of 161 
treatment effects in different trials was tested by the I2 statistic. Statistical 162 
heterogeneity was recorded when the p value of the test of heterogeneity was 0.1 or 163 
lower or the I2 value was 0.5 or greater. In a post-hoc analysis of the ALLHAT trial, the 164 
effects of ‘no previous treatment’ versus ‘previous treatment’ for high BP were 165 
estimated using a Cox proportional hazard model. As this analysis was a comparison 166 
of non-randomised groups, the two groups were adjusted for an imbalance in baseline 167 
characteristics (e.g. age, race, sex, diabetes mellitus, education, body mass index, 168 
smoking, aspirin use, randomised group, BP, total cholesterol, serum glucose and 169 
creatinine), as per Nelson et al in the ANBP2 study23. The observed (O), expected 170 
event (E) and variance (V) in ALLHAT were estimated from adjusted HR as 171 
recommended by Tierney et al 29 and then pooled with the corresponding O, E and V 172 
in Oslo and PREVEND-IT. The threshold of a significant effect was set at 0.05.  173 
We conducted a sub-group analysis based on baseline risk of CVD where data 174 
were available. We stratified participants by the baseline estimated 10-year 175 
Framingham risk score for fatal and non-fatal CVD events using  thresholds of lower 176 
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than 20% (low risk), 20-30% (moderate risk) and higher than 30% (high risk) over 10 177 
years 30, 31. We estimated the relative risk for all-cause and CVD mortality in each 178 
group and tested for difference between the groups. Data synthesis and analyses were 179 
performed in Review Manager 5 32. We extracted data based on intention-to-treat 180 
principles. 181 
Sensitivity analysis  182 
An analysis restricted to placebo/untreated controlled RCTs was performed to 183 
investigate the impact of the observational study on the pooled outcomes. Different 184 
statistical methods were also used to check the robustness of the results25-28. 185 
Results 186 
Result of the searches 187 
The database searches identified 6012 records and three articles were identified from 188 
other sources (Figure Appendix 1 shows the flowchart of studies). After removal of 189 
duplicates 4090 articles were screened. Eighty nine articles were screened in full-text 190 
and 3 studies (Oslo, PREVEND-IT and ALLHAT) from 11 articles were included in the 191 
review. Aggregate unpublished data from the ALLHAT and individual data of 192 
PREVEND-IT trial were provided by the trial investigators.  193 
One trial excluded from the review included participants with mildly elevated diastolic 194 
BP (90-115 mmHg): USPHS 197733, 34.   Although USPHS did not have a post-trial 195 
phase, the trial was followed for up to 10 years. No information on the proportion of 196 
participants with mildly elevated systolic BP was reported. Based on the baseline 197 
systolic BP148±15 mmHg, it is likely that less than 80% of participants had systolic BP 198 
less than 160 mmHg. The intervention was a combination of a diuretic and rauwolfia 199 
serpentine that had limited clinical use in current practice because of the risk of side 200 
effects and availability. Thus USPHS was excluded in the current systematic review 201 
and meta-analysis.  202 
Characteristics of included studies and risk of bias 203 
The review included published data from the Oslo trial, unpublished aggregate data 204 
from the ALLHAT and individual data from the PREVEND-IT. In the ALLHAT trial, we 205 
used data based on whether participants had previously been treated with BP lowering 206 
agents or not, that is a comparison on a difference in treatment status at baseline 207 
between the two groups rather than a randomised comparison. ALLHAT participants 208 
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were followed for a mean of 4.9 years in the in-trial period and 14 years over the in- 209 
and post-trial period.  As the original ALLHAT trial 35 reported beneficial effects from 210 
BP lowering treatment (e.g. Chlorthalidone 12.5 to 25 mg/d vs amlodipine 2.5 to 10 211 
mg/d vs lisinopril 10 to 40mg/d) within the trial period, the majority of participants from 212 
all arms of the trials received active treatment in the post-trial phase, so there is likely 213 
to be little cross-over between the early treatment and delayed treatment comparison 214 
groups. Although some participants in the Oslo trial may have had a diastolic BP 215 
exceeding 110 mmHg, nearly 80% of Oslo participants had systolic BP lower than 160 216 
mmHg, so we included the published data of this trial. Oslo participants were 217 
randomised to active treatment (Hydrochlorothiazide 50 mg) or no active treatment. 218 
Oslo reported 10-year36 and 40-year37 follow-up of all-cause mortality and CHD 219 
mortality, thus the results of the 40-year study were included in the current review.   In 220 
PREVEND-IT trial, participants were originally randomised either to active treatment 221 
(Fosinopril 20 mg) or placebo. The mean follow-up period ranged from 3.3-4.4 years 222 
for the in-trial phase and 9.4-10.7 years for the overall period. 223 
The baseline risk for participants in ALLHAT was higher than the other two trials as it 224 
included participants with elevated BP and at least one other CVD risk factor (e.g. 225 
history of type 2 diabetes, current cigarette smoking, high-density lipoprotein 226 
cholesterol of less than 0.91 mmol/L). PREVEND-IT included healthy subjects from 227 
the general population with persistent microalbuminuria, and the Oslo trial included 228 
men with mildly elevated BP (defined as systolic BP 150-179 mmHg and diastolic BP 229 
less than 110 mmHg). More details on the characteristics of the included and excluded 230 
studies are provided in Table appendix 2 and 3. 231 
The baseline characteristics of the participants included in the review showed no 232 
significant differences between study groups in the PREVEND-IT and Oslo trials 233 
(Table 1). ALLHAT participants had a higher proportion of patients with diabetes, and 234 
contributed to a higher proportion of participants with early treatment having type 2 235 
DM. Participants with early treatment in the ALLHAT trial were also more likely to be 236 
black, female, non-smoker and had higher estimated 10-year CVD risk scores. We 237 
adjusted for these imbalances in multivariable models. Noticeably, Oslo included men 238 
only and had higher baseline systolic BP than the other two trials.  239 
Risk of bias (Table 2) 240 
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In Table 2, We assessed the ALLHAT data to be at serious risk of bias due to residual 241 
confounding as a result of the use of post-hoc non-randomised data from the trial. 242 
Although the outcome measurements in the post-trial phase of the PREVEND-IT and 243 
Oslo trials were unblinded, the primary outcomes considered in this analysis are 244 
generally objective (all-cause and cardiovascular mortality). Thus, the overall risk of 245 
bias for the PREVEND-IT and Oslo trials were judged as ‘Low risk’.  More details on 246 
the assessment of the risk of bias in each trial are presented in Table appendix 4.   247 
Short- and long-term all-cause and CVD mortality (Figure 1) 248 
The analyses on short- and long-term all-cause mortality and short-term CVD mortality 249 
included 4746 participants from three trials, with 80% originating from the ALLHAT 250 
trial.  As the Oslo trial separately reported aggregate data for CHD and stroke, these 251 
subjects were excluded in the analysis of long-term CVD mortality, leaving 3961 252 
participants in the analysis. There were 301 deaths in total and 102 deaths due to CVD 253 
recorded in the in-trial period, and 1871 total deaths and 312 CVD deaths during the 254 
post-trial period (Table appendix 5).  255 
In Figure 1, we observed no statistically significant difference in all-cause mortality in 256 
either the short- or long-term (short-term OR 0.95, 95%CI 0.68-1.32; long-term OR 257 
0.90, 95%CI 0.78-1.04) for those with delayed BP lowering treatment relative to those 258 
with earlier treatment. Similarly, no difference was found for CVD mortality (short-term 259 
OR 0.90, 95%CI 0.51-1.59; long-term OR 0.79, 95% CI 0.55-1.14).  260 
CVD events (Figure 1) 261 
Two trials (Oslo and PREVEND-IT) including 934 participants contributed to the 262 
analysis of major CVD events in the short-term, with 69 events recorded in the in-trial 263 
phase of the Oslo and PREVEND-IT trials. However, only PREVEND-IT (149 264 
participants, 19 events) recorded long-term outcomes 38. As provided in Figure 1, we 265 
found no statistically significant difference in major CVD events for those with delayed 266 
drug treatment in either the short or long-term (short-term OR 1.35, 95% 0.83-2.21; 267 
long-term OR 1.02, 95% 0.39-2.66).  268 
Subgroup analysis by 10-year Framingham risk score  269 
Data were available to stratify participants in ALLHAT and PREVEND-IT into low, 270 
moderate and high risk of CVD. More than half of the included participants were in the 271 
high risk group, primarily due to the inclusion criteria of the ALLHAT study. The effects 272 
of delayed BP lowering drug treatment were consistent among the three groups 273 
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(p=0.46 and p=0.79 for the test of subgroup differences in overall all-cause and CVD 274 
mortality respectively) (Figure 2 and Figure 3).  275 
Sensitivity analysis  276 
Using different methods (DerSimonian‐Laird between‐study variance estimator and 277 
Wald‐type confidence intervals , DerSimonian‐Laird between‐study variance estimator  278 
and  Hartung‐Knapp‐Sidik‐Jonkman  adjusted confidence intervals, Paule‐Mandel 279 
between‐study variance estimator and Hartung‐Knapp‐Sidik‐Jonkman confidence 280 
intervals) to pool the aggregate data did not change the main findings in all-cause and 281 
CVD mortality as presented in Table appendix 6.  282 
An analysis restricted to the data from the randomised trials only (PREVEND-IT and 283 
Oslo), were similar to the main analyses, with no statistically significant difference in 284 
for short-term all-cause mortality (OR 0.99, 95% CI 0.43-2.27) or long-term all-cause 285 
mortality (OR 0.94, 95% CI 0.70-1.28) or short- or long-term CVD mortality (short-term 286 
OR 1.26, 95% CI 0.42 - 3.76; long-term OR 2.23, 95%CI 0.23-21.84) (Table appendix 287 
7).  288 
A sensitivity analysis adjusting for baseline differences, showed no substantial 289 
difference between the adjusted and crude hazard ratio for any outcome (Table 290 
appendix 8). 291 
 Discussion 292 
The present systematic review and meta-analysis of studies with extended post-trial 293 
phase showed no statistically significant difference in all-cause and CVD mortality for 294 
participants with ‘delayed’ drug treatment at a systolic BP threshold of 140 mmHg in 295 
middle-aged adults even when the follow-up was extended for more than 10 years. 296 
Due to the small number of events in the in-trial period, subgroup analyses were 297 
performed only for long-term all-cause and CVD mortality. No heterogeneity of 298 
‘delayed’ treatment effects was found across the low, moderate and high CVD risk 299 
subgroups. 300 
Our findings are similar to two earlier systematic reviews in middle-aged adults without 301 
previous CVD39 and in middle-aged adults both with and without previous CVD17. 302 
Trials in these reviews had follow-up durations of approximately five years, except for 303 
the USPHS study34. The USPHS was followed for 7-10 years and did not show any 304 
difference in early vs delayed treatment regarding all-cause mortality with a RR 0.51 305 
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(0.09-2.74). Results from USPHS may not be considered relevant to current 306 
populations, however, as this trial used rauwolfia, which is no longer recommended 307 
treatment. Similar to our short-term results, the SHEP1 and Syst-Eur2 trials did not 308 
record any substantial benefits of ‘early’ treatment for all-cause or CVD mortality after 309 
an in-trial follow-up of five and two years respectively. However, the effects on CVD 310 
mortality became statically significant with a HR 0.86 (0.76-0.97) when the SHEP trial 311 
was extended to 14 years40 and this ‘legacy effect’ remained significant at the 22-year 312 
follow-up41. The reduction in mortality in Syst-Eur remained non-statistically significant 313 
after a total follow-up of 6 years42, indicating that a longer time for follow-up is required 314 
to observe significant ‘delayed benefits’. The SHEP and Syst-Eur trials had a ‘placebo’ 315 
arm when participants experienced ‘placebo’ run-in or withdrawal phase. However 316 
these trials were aimed at the elderly with much higher systolic BP values of 160 317 
mmHg or over compared to the participants considered in our review. HOPE-3 trial in 318 
intermediate risk participants also observed no statistically significant difference 319 
between the effect of an active treatment and placebo in all-cause or CVD mortality 320 
and major CVD event after 5.6 years of follow-up. 321 
Benefits of ‘active treatment’ or harms of ‘no treatment’ may require longer than ten 322 
years to become evident, particularly for mortality outcomes in middle-aged adults with 323 
mildly elevated BP who are at low CVD risk. This is the group that where treatment 324 
with blood pressure lowering medication is not clearly of benefit. We have attempted 325 
in this review to determine if treatment can safely be delayed in this treatment group. 326 
In this review, the average Framingham risk score was >20%, and so is higher than 327 
the low risk patients we would consider where treatment could be delayed. Even in 328 
this review, however, no clear evidence of early treatment was observed. The included 329 
ALLHAT and Oslo trial37 were extended to 14 and 40 years respectively, with no 330 
substantial ‘legacy effect’ on all-cause or CVD mortality of delayed treatment 331 
observed, and we observed consistent results across the low, moderate and high CVD 332 
risk subgroups.   333 
Strengths and limitation 334 
This is the first study to systematically review the medical evidence to determine if 335 
delaying BP lowering treatment for middle-aged adults with a systolic BP between 140 336 
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and 159 mmHg results in an increase in all-cause or cardiovascular mortality in the 337 
short or long term.   338 
In spite of vigorous efforts in accessing individual data to identify eligible participants, 339 
only three trials with 4746 participants could be included in the current review. Given 340 
the much larger size of ALLHAT trial, the overall results were heavily influenced by the 341 
results of this trial. In the ALLHAT trial, information on how long before the start of the 342 
trial participants had been on BP lowering treatment was not collected and even if it 343 
was, we could not truly know how long someone was hypertensive before it was noted. 344 
However, in sensitivity analyses on short- and long-term all-cause mortality, the results 345 
of analyses excluding the ALLHAT trial were generally consistent with the overall 346 
results.  347 
This review did not examine CHD and stroke mortality separately. Given the small 348 
number of studies and the potential for CHD and stroke to be affected by different 349 
classes of BP lowering medication 43, 44, we were only able to assess overall and total 350 
CVD mortality. 351 
The three included trials lacked BP lowering drug treatment information in the post-352 
trial phase except that an equal percentage of participants receiving drug therapy were 353 
reported in PREVEND-IT and Oslo trial. Given the ‘positive’ findings of the original 354 
ALLHAT trial, we believe it is likely that a substantial proportion of both arms of the 355 
trial would have used BP lowering therapy after the trial period.  356 
We used the Peto method for meta-analysis because of the small number of included 357 
studies. While it is true that the Peto method is open to bias when including studies 358 
with imbalance in the comparison groups, this only becomes apparent in combination 359 
with a large treatment effect24. Also, sensitivity analyses using different statistical 360 
methods provided similar pooled effects (Appendix 6).  361 
One of the barriers to adopting the absolute risk approach for decisions regarding BP 362 
lowering treatment is the concern that early treatment of mildly elevated BP is 363 
necessary to prevent pathological changes that result in CVD events. Our systematic 364 
review and meta-analysis showed no clinically adverse ‘legacy effect’ on mortality 365 
outcomes of not treating middle-aged adults at a systolic BP between 140 and 159 366 
mmHg. This study contributes to an area of major concern raised by many clinicians 367 
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that early treatment of mildly elevated systolic BP is necessary to prevent CVD events 368 
in primary prevention population. 369 
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Figure 1. Forest plot for outcomes during the in-trial and overall follow-up. 535 
CI: Confidence interval, ALLHAT: Antihypertensive and Lipid-Lowering Treatment to 536 
Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: Prevention of Renal and 537 
Vascular Endstage Disease Intervention Trial. 538 
Figure 2. Forest plot for overall all-cause mortality in subgroup by 10-year 539 
Framingham risk score. 540 
CI: Confidence interval, ALLHAT: Antihypertensive and Lipid-Lowering Treatment to 541 
Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: Prevention of Renal and 542 
Vascular Endstage Disease Intervention Trial. 543 
Figure 3. Forest plot for overall CVD mortality in subgroup by 10-year 544 
Framingham risk score.  545 
CI: Confidence interval, ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent 546 
Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: Prevention of Renal and Vascular 547 
Endstage Disease Intervention Trial. 548 
  549 
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 550 
Table 1.Baseline characteristics of included participants 551 
*: p<0.05 for the comparison between the delayed and early treatment groups. ALLHAT: 552 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid-Lowering Trial, 553 
PREVEND-IT: Prevention of Renal and Vascular Endstage Disease Intervention Trial. NA: not available. 554 
SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, BMI: Body Mass Index, HDL: High Density 555 
Lipoprotein cholesterol, FRS: Framingham Risk Score. 556 
557 
Characteristics Delayed Early 
 ALLHAT PREVEND-IT Oslo ALLHAT PREVEND-IT Oslo 
Number of 
observations, n 
509 70 379 3303 79 406 
Age (mean + SD, 
years) 
59.5 + 2.9 52.3±8.0 
45.2±2.8 
59.5 + 2.9 50.3±8.2 
45.3±2.9 
Black, % 34.6* 0 NA 43.6 1.3 NA 













31.3 +7.1 27.7±4.7 
NA 
Diabetes† (%) 41.7* 2.9 0 51.1 2.5 0 
SBPs (mean + 
SD, mmHg): 
147+ 7* 147± 6 
155±8 
146 + 8 148±6 
156±7 









7.2+ 3.5* 5.3±1.4 
6.0±0.6 




5.6 + 1.1 6.1±1.1 7.1±1.2 5.7 + 1.2 6.1±0.9 7.1±1.2 
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Table 2 Risk of bias  558 





































ALLHAT Serious Low Moder
ate 
NA NI NI Low NA Serious 
PREVEN
D-IT 
NA NA NA Low Low Low Low Low Low 
Oslo NA NA NA Low Low Low Low Low Low 
NA – not applicable, NI: No Information. ALLHAT: Antihypertensive and Lipid-Lowering Treatment to 559 
Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: Prevention of Renal and Vascular 560 
Endstage Disease Intervention Trial 561 
